Roche Diabetes Care
Roche Diabetes Care, a division of F. Hoffmann-La Roche Ltd, develops and markets the Accu-Chek glucose monitoring portfolio and mySugr digital platform under its Integrated Personalised Diabetes Management (iPDM) framework, serving people with diabetes, caregivers, and healthcare providers globally.
- Company typePrivate
- Founded1896
- HeadquartersBurgdorf, Switzerland
- Headcount5,001–10,000
- GTM typeB2C
- OfferingHardware or Manufacturing
What Roche Diabetes Care does
Roche Diabetes Care is the diabetes care division of F. Hoffmann-La Roche Ltd, a Swiss multinational healthcare company founded in 1896 in Basel. The division operates with nearly 50 years of experience in diabetes care, offering a portfolio under the Accu-Chek and mySugr brands that spans blood glucose meters, test strips, insulin delivery systems, and mobile-app-based digital diabetes management. Underlying this portfolio is the Integrated Personalised Diabetes Management (iPDM) platform, which connects hardware devices (Bluetooth-enabled glucometers and insulin pens) with software (the mySugr app and data analytics) to enable continuous data flow among people with diabetes, caregivers, and healthcare providers.
The division generates revenue primarily through hardware and consumables sales (glucose meters, test strips, insulin delivery systems) sold directly to consumers via pharmacies and online channels, through healthcare providers and clinics, and via digital-first distribution through the mySugr app platform. A secondary, recurring/subscription revenue stream comes from the mySugr digital health platform. Customer segments include individuals living with diabetes (primary), their caregivers (secondary), and physicians, diabetes educators, and healthcare systems (primary clinical channel). The division competes in the global CGM and blood glucose monitoring market alongside Abbott Diabetes Care, Dexcom, Medtronic, and Tandem Diabetes Care, and serves virtually every market worldwide through the Roche Group's distribution infrastructure.
Roche Diabetes Care holds the 5th-largest CGM calibration patent portfolio globally and continues to invest in R&D for connected care, evidenced by 2025 partnerships in Asia Pacific across India, China, Japan, Singapore, and Vietnam, and clinical validation work such as a multi-center study in India demonstrating HbA1c reduction from 8.8% to 7.5% when pairing the Accu-Chek Instant with the mySugr app. The division operates with 5,001-10,000 employees and reports financials only at the consolidated F. Hoffmann-La Roche Ltd level.
Roche Diabetes Care firmographics
Firmographics- Name
- Roche Diabetes Care
- Legal name
- F. Hoffmann-La Roche Ltd
- Website
- https://rochediabetes.com
- Company type
- Private
- Founded year
- 1896
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Roche Diabetes Care, a division of F. Hoffmann-La Roche Ltd, develops and markets the Accu-Chek glucose monitoring portfolio and mySugr digital platform under its Integrated Personalised Diabetes Management (iPDM) framework, serving people with diabetes, caregivers, and healthcare providers globally.
- Ownership category
- akta.pro rank
Roche Diabetes Care industry classification
Industry- Product category
- Blood Glucose Monitoring & Diabetes Management Devices
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Custom Computer Programming Services (541511)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
- akta.pro secondary industries
- Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Diabetes (General) (HLAKADAA)
Keywords
Where Roche Diabetes Care is headquartered
LocationHeadquarters
- HQ city
- Burgdorf
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Roche Diabetes Care business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Medical Device and Consumables Sales: Revenue generated from glucose monitoring devices, test strips, insulin delivery systems, and related consumables sold to people with diabetes, healthcare providers, and caregivers
- Digital Health Solutions: Digital applications and software platforms including mySugr app services for diabetes management
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Roche Diabetes Care product offering
Product offeringCore offering
Roche Diabetes Care develops, manufactures, and sells blood glucose monitoring systems (under the Accu-Chek brand), insulin delivery systems, and digital diabetes management solutions (including the mySugr mobile app). Its offerings are unified through the Integrated Personalised Diabetes Management (iPDM) platform that combines connected meters, consumable test strips, and software to support people with diabetes and their care teams.
Product overview
Roche Diabetes Care offers a unified portfolio of diabetes management solutions built around two primary brands: Accu-Chek (glucose monitoring hardware including Bluetooth-enabled meters and test strips) and mySugr (digital health app for connected data management and tracking). These products are integrated through the Integrated Personalised Diabetes Management (iPDM) platform, which connects glucose monitoring, insulin delivery, and digital solutions to enable seamless data flow between patients, caregivers, and healthcare providers. The portfolio is designed to address the full diabetes care journey from initial diagnosis through ongoing management.
Differentiator
Problem solved
Functional benefit
Brands
- Accu-Chek: Brand for glucose monitoring devices, insulin delivery systems, and related diabetes care products including the Accu-Chek Instant glucometer
- mySugr
Products and services
- Accu-Chek blood glucose meters (e.g., Accu-Chek Instant, Accu-Chek Guide, Accu-Chek Mobile)
Quantifiable outcome
- HbA1c reduction from 8.8% to 7.5% in type 2 diabetes patients using Accu-Chek Instant with mySugr app over 3 months
Companies that use Roche Diabetes Care
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Roche Diabetes Care technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Roche Diabetes Care partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Strategic Partners in Asia PacificcoreRoche Diabetes Care is expanding its presence in the Asia Pacific digital diabetes management market through strategic partnerships and product launches, with key market players including Roche, Dexcom, Medtronic, Abbott, and Tandem Diabetes Care competing in this high-growth region.
- Patent Ecosystem Partners (Abbott, Medtronic MiniMed, Dexcom, University of Padua)coreRoche Diabetes Care is identified as one of five principal assignees in the CGM calibration patent landscape, indicating significant technology development and potential cross-licensing relationships within the diabetes technology ecosystem. The company holds approximately 5th position among major patent filers in this space.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Roche Diabetes Care competitors and assessment
Company assessmentDirect peers
- Dexcom: Dexcom is a leading pure-play continuous glucose monitor manufacturer competing head-to-head with Roche's diabetes portfolio. It is one of the five principal CGM calibration patent assignees and a direct competitor in glucose monitoring, with a much narrower product focus than Roche Diabetes Care.
- Abbott Diabetes Care: Abbott's Diabetes Care division produces the FreeStyle Libre CGM and related BGM products, directly overlapping Roche's Accu-Chek and iPDM offerings. It is named alongside Roche as one of the top five CGM calibration patent filers, making it one of the closest direct competitors.
- LifeScan (OneTouch): LifeScan markets the OneTouch brand of blood glucose meters and test strips, directly competing with Accu-Chek in the BGM category. It serves similar patient and HCP segments and historically has been one of Roche's primary BGM competitors globally.
- Medtronic Diabetes: Medtronic's Diabetes division offers integrated insulin pumps, CGM sensors (Guardian), and closed-loop systems (MiniMed). It competes directly with Roche's insulin delivery and glucose monitoring portfolio and is one of the five principal CGM patent assignees identified alongside Roche.
- Ascensia Diabetes Care: Ascensia produces the Contour blood glucose monitoring portfolio and competes directly with Accu-Chek in BGM meters, test strips, and increasingly connected diabetes solutions. Both companies target similar patient and HCP segments across global markets.
- Tandem Diabetes Care: Tandem makes insulin pumps (t:slim, t:sport) with integrated CGM connectivity, competing in the insulin delivery and connected diabetes management space alongside Roche's portfolio. It is identified as one of the key Asia Pacific digital diabetes management competitors.
Broad incumbents
- Novo Nordisk: Novo Nordisk is the global leader in insulin and broader diabetes pharmaceuticals, with growing connected device and digital health initiatives. It overlaps with Roche's diabetes ecosystem as a broader incumbent player in diabetes care, though primarily through therapeutics rather than BGM hardware.
- Sanofi Diabetes: Sanofi is a major diabetes pharmaceutical manufacturer (insulins, GLP-1s) with growing digital diabetes management efforts. It competes with Roche Diabetes Care at the broader diabetes care level and is identified among major competitors in Asia Pacific digital diabetes management markets.
Regional players
- Ypsomed: Ypsomed is a Swiss-based manufacturer of insulin delivery systems and pen needles serving European and select global markets. It competes with Roche's insulin delivery portfolio, particularly in Europe where Roche Diabetes Care is headquartered.
Emerging players
- Insulet Corporation: Insulet's Omnipod patch pump competes in the wearable insulin delivery category that overlaps with Roche's insulin delivery offerings. As a focused patch-pump innovator, it represents a more specialized competitor in insulin delivery rather than full-stack diabetes management.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Roche Diabetes Care social profiles
Digital presenceRoche Diabetes Care financial estimates
Financial estimateRevenue estimate
Valuation estimate
Roche Diabetes Care leadership team
Management profileNumber of profiles
Profiles2 records
Roche Diabetes Care funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Roche Diabetes Care M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Roche Diabetes Care
What does Roche Diabetes Care do?
Roche Diabetes Care develops, manufactures, and sells blood glucose monitoring systems (under the Accu-Chek brand), insulin delivery systems, and digital diabetes management solutions (including the mySugr mobile app). Its offerings are unified through the Integrated Personalised Diabetes Management (iPDM) platform that combines connected meters, consumable test strips, and software to support people with diabetes and their care teams.
Is Roche Diabetes Care a public or private company?
Roche Diabetes Care is a private company. It is classified as public and is currently operating.
When was Roche Diabetes Care founded?
Roche Diabetes Care was founded in 1896. It employs 5,001 to 10,000 people.
Where is Roche Diabetes Care based?
Roche Diabetes Care is headquartered in Burgdorf, Switzerland, in the Europe region.
How does Roche Diabetes Care make money?
Two revenue lines are on record. Medical Device and Consumables Sales are the primary driver. The others are digital Health Solutions.
Who are Roche Diabetes Care's main competitors?
Direct peers on record are Dexcom, Abbott Diabetes Care, LifeScan (OneTouch), Medtronic Diabetes, Ascensia Diabetes Care and Tandem Diabetes Care. Broad incumbents are Novo Nordisk and Sanofi Diabetes. Ypsomed is listed as a regional player. Insulet Corporation is listed as an emerging player.
Does Roche Diabetes Care have an API?
No public API is recorded for Roche Diabetes Care.
What industry is Roche Diabetes Care in?
Roche Diabetes Care's product category is Blood Glucose Monitoring & Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 3345 and its SIC code is 3841.